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Background: The current status of the eﬃcacy of implantable cardioverter-deﬁbrillator
(ICD) and cardiac-resynchronization therapy with implantable deﬁbrillator (CRT-D) in
patients with left ventricular dysfunction needs to be clariﬁed.
Methods and Results: From the Japanese Cardiac Device Treatment Registry database, a
total of 1,584 patients who had an LVEF 5 40% and had an ICD or CRT-D were selected as
subjects in this study. The diﬀerence in the clinical characteristics between the primary and
secondary prevention groups and the transition of the indications for device implantation over
time were examined. Primary prevention gradually increased up to about 50% in all patients.
The implantations of ICD/CRT-D for primary prevention in ischemic hear disease was
signiﬁcantly lower than that in dilated cardiomyopathy (33% vs 51%; p < 0:0001). The
number of implantations for CRT-D for primary prevention increased dramatically over a
one-year period.
Conclusions: In Japan, the implantable deﬁbrillator devices for primary prevention was
signiﬁcantly lower in ischemic heart disease compared with dilated cardiomyopathy. Further,
an extension of the indications for ICD/CRT-D implantations has recently been occurring,
especially with CRT-D devices for primary prevention.
(J Arrhythmia 2008; 24: 133–140)
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Introduction
It is well known that implantable cardioverter-
deﬁbrillators (ICD) and cardiac-resynchronization
therapy with implantable deﬁbrillators (CRT-D) are
useful for improving the prognosis and/or sudden
cardiac death event rate in patients with heart failure
and fatal ventricular arrhythmias.1–3) Further, major
recent mega-trials4–8) performed in the USA and
Europe have indicated that ICD/CRT-Ds also have
improved the survival in patients with heart failure
and even in those without a history of cardiac arrest
and/or fatal ventricular arrhythmias.
In Japan, ICD was approved by the Japanese
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Ministry of Health, Labor and Welfare (MHLW) in
1996. The ﬁrst guidelines for ICD were reported by
the Japanese Circulation Society in 2001.9) Cardiac-
resynchronization therapy (CRT) and CRT-D were
approved in 2004 and 2006, respectively. Further,
the internet registry, the Japanese Cardiac Device
Treatment Registry (JCDTR)10,11) which was admin-
istered by the Japanese Heart Rhythm Society started
simultaneously started. New guidelines set forth by
the Japanese Circulation Society were begun in
2007,12) and patients with an LVEF of less than or
equal to 35%, drug resistant chronic heart failure
(NYHA III/IV) with or without a history of fatal
ventricular arrhythmias were classiﬁed as class IIa
indication.12)
However, the impact of introduction of CRT-D
and the revision of guidelines for device implanta-
tions on the selection of shock device have not been
examined in Japanese patients with heart failure.
Therefore, the purpose of this study was to compre-
hend the current status of implantable deﬁbrillator
devices (ICD/CRT-D) in patients with left ventric-
ular dysfunction and the indication for those on the
basis of the data from the JCDTR.
Methods
The JCDTR Questionnaire consisted of three
parts, implantation information, patient character-
istics and pharmacologic treatment at the time of the
implantation (Table 1). The data was collected by on-
line registry using the university hospital medical
information network (UNIM). Approval proceeding
for this study was performed by each participating
institution.
A total of 2,924 patients were enrolled into the
JCDTR from 155 facilities. 1,584 patients (54% of
the total patient population) who had an LVEF 5
40% and ICD/CRT-D implanted from January 1st
2006 to May 9th 2008, were selected as the subjects
for this study.
We investigated 1) the diﬀerence of clinical
characteristics in patients with an ICD/CRT-D
between those that received the device for primary
vs secondary prevention for sudden cardiac death,
2) the number of implantations and complications
during the ICD/CRT-D implantations, 3) the tran-
sition of indications for implantation of the ICD/
CRT-D over the years.
Statistical Analysis: The values for the continuous
variables are presented as the mean þ= the
standard deviation, and the values for categorical
variables are presented as percentages. The dif-
ferences in the clinical characteristics and medica-
tions used at baseline between those receiving a
device for primary prevention and those for secon-
dary prevention were tested by the chi-square test.
Results
Clinical characteristics
The number of patients receiving a device for
primary prevention was 673, and it was lower than
that for secondary prevention, 911. There were no
signiﬁcant diﬀerences in the age or ratio of males to
females between the primary and secondary preven-
tion groups (Table 2).
There was no signiﬁcant diﬀerence in the distri-
bution of structural heart disease except for ischemic
heart disease (IHD) and dilated cardiomyopathy
Table 1 JCDTR Questionnaire
Information on the implantation
1. Name of Institute, Date of Registry
2. Age and sex of the Patients
3. Date of the implantation
4. Name of the operators
5. The purpose of the implantation
primary or secondary prevention
6. Implantation indications on the
basis of the Japanese Guidelines
7. Name of the implanted device
8. Implanted leads
atrium, ventricle 1, ventricle 2
9. Deﬁbrillation threshold
minimum energy for deﬁbrillation
10. Complications
Patient Characteristics
1. Patient history
VT, VF, torsades de pointes, syncope,
unknown
2. Structural heart disease
3. Disease other than cardiac disease
4. NYHA classiﬁcation
5. LVEF, measurement methods used
6. CAG
7. QRS duration and dyssynchrony
8. Signal averaging
9. TWA
10. EPS
11. Holter ECG
Medications given at implantation
1. Antiarrhythmic drugs
2. Diuretics, ACE/ARB, ext
3. Anitiplatelets or anticoagulants
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(DCM) between the primary and secondary preven-
tion groups (Figure 1, Table 2). Both IHD and DCM
were major structural heart diseases in the patients
with an ICD/CRT-D device, and occupied in 84%
in the primary prevention group and 83% in the
secondary prevention group. The implantation of
Table 2 Clinical characteristics in the patients with an ICD/CDT-D implanted for primary and secondary
prevention
Primary Secondary Total
primary
vs
secondary
Numbers 673 911 1,584
Age 64 13 65 11 64 12 p ¼ 0.58
Male/Female (ratio) 3.1 3.6 3.4 p ¼ 0.18
n (%) n (%) n (%)
1) Structural Heart Disease
IHD 219 (33) 440 (48) 659 (42) p < 0.0001
DCM 344 (51) 317 (35) 661 (42) p < 0.0001
HCM 23 (3) 37 (4) 60 (4) n.s
HHD 4 (1) 12 (1) 16 (0.1) n.s
VHD 30 (5) 32 (4) 62 (4) n.s
CHD 1 (0.1) 9 (1.) 10 (0.6) n.s
Miscellaneous 52 (8) 64 (7) 116 (7) n.s
2) NYHA
I 42 (6) 133 (15) 175 (11) p < 0.0001
II 179 (27) 382 (42) 561 (35) p < 0.0001
III 386 (57) 302 (33) 688 (43) p < 0.0001
IV 66 (10) 94 (10) 160 (10) P ¼ 0.738
3) LVEF 26 7% 29 8% 28 8% p < 0.0001
4) EPS 237 (35) 358 (39) 595 (38) p ¼ 0.097
IHD: ischemic heart disease, DCM: dilated cardiomyopathy, HCM: hypertrophic cardiomyopathy, HHD:
hypertensive heart failure, VHD: valvular heart disease, CHD: congenital heart disease, EPS: electro-
physiogical study, LVEF: left ventricular ejection fraction
Primary prevention group
total 673 patients
n (%)
9(1%)
32(4%)
12(1%)
37(4%)
64(7%)
440(48%)
317(35%)
1(0%)
52(8%)
219(33%)4(1%)
23(3%)
344(51%)
30(4%)
Secondary prevention group
total 911 patients
n (%)
 IHD  
 VHD   CHD   Miscellaneous 
 DCM   HCM   HHD
Figure 1 Underlying heart disease in patients with an ICD/CRT-D
IHD: ischemic heart disease, DCM: dilated cardiomyopathy, HCM: hypertrophic cardiomyopathy, HHD: hypertensive heart failure, VHD:
valvular heart disease, CHD: congenital heart disease, LVEF: left ventricular ejection fraction
Shimizu A Deﬁbrillator devices in patients with LV dysfunction
135
ICD/CRT-D for secondary prevention in IHD was
signiﬁcantly higher than that in DCM (48% vs 35%;
p < 0:0001, Figure 1 and Table 2). Inversely, the
implantation of ICD/CRT-D for primary prevention
in IHD was signiﬁcantly lower than that in DCM
(33% vs 51%; p < 0:0001, Figure 1 and Table 2).
In the distribution of the NYHA classiﬁcation,
the percentage of class I and II in the secondary
prevention group was higher than those in the
primary prevention group. Inversely, the percentage
of class III in the primary prevention group was
higher than that in the secondary prevention group
(Table 2). LVEF in the primary prevention group was
signiﬁcantly lower than that of the secondary
prevention group (Table 2). There was no signiﬁcant
diﬀerence on the ratio of electrophysiological studies
(EPS) performed between primary and secondary
prevention groups (35% vs 39%, p ¼ 0:097, Table 2).
In the medications used for the arrhythmias, there
were no signiﬁcant diﬀerences between the primary
and secondary prevention groups, except for the
class III drugs (Table 3). In particular, the percentage
of amiodarone given for secondary prevention was
much higher than that for primary prevention (64%
versus 37%, p < 0:0001). The percentage of the
medications used for heart failure, such as diuretics,
-blockers, ACE/ARBs, spironolactone and digoxin,
given for the primary prevention was signiﬁcantly
higher than that for the secondary prevention
(Table 3).
Number of implantations and complications in
ICD and CRT-D implantations
The total number of ICD implantations was 750
and that of CRT-D implantations was 804. With
regard to the so called upgrade, the number of
implantations upgraded from an ICD to a CRT-D
device was 22 and that from CRT-P to CRT-D
device was 8, so far their number of those patients
was very small, and accounted for less than 2% of all
implantations.
The incidence of complications during the ICD
and CRT-D implantations, was very low. Further,
the percentage of total complications was signiﬁ-
cantly higher for CRT-D than ICD implantation
(Table 4).
Number of ICD and CRT-D implantations and
change in the purpose for their implantations
(Figure 2)
ICD and CRT-D (the upper panels): The percent-
age of both ICD and CRT-D implantations for
primary prevention (22%) increased dramatically
from the ﬁrst half of the year in 2006 to the ﬁrst half
Table 3 Medications for arrhythmias and congestive heart failure at the registry
Primary Secondary Total
primary
vs
secondary
Numbers 673 911 1,584
n (%) n (%) n (%)
1) Antiarrhythmic Medications
Class IA 11 (2) 8 (1) 19 (1) n.s
Class IB 33 (5) 62 (7) 95 (6) n.s
Class IC 3 (0.4) 10 (1) 13 (0.8) n.s
Class III 272 (40) 623 (68) 895 (57) p < 0.0001
amiodarone 248 (37) 582 (64) 530 (34) p < 0.0001
sotalol 19 (3) 36 (4) 55 (4) n.s
Ca antagonist 59 (9) 74 (8) 133 (8) n.s
2) Medications given for congestive heart failure
Diuretics 521 (77) 624 (69) 1,145 (72) p < 0.0001
ACE/ARB 510 (76) 632 (69) 1,062 (67) p ¼ 0.005
-blockers 467 (69) 590 (65) 1,057 (67) p ¼ 0.053
carvedilol 427 (63) 533 (59) 960 (61) p ¼ 0.046
Spironolactone 321 (48) 351 (39) 672 (42) p ¼ 0.0003
Digoxin 150 (22) 121 (13) 271 (17) p < 0.0001
Nitorate 79 (12) 118 (13) 197 (12) n.s
-blockers 1 (0.1) 2 (0.2) 3 (0.2) n.s
Statin 169 (25) 222 (24) 391 (25) n.s
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of the year in 2007. The total number of implanta-
tions for secondary prevention was 911, and it was
greater than that for primary prevention, 673.
However, the ratio of primary prevention to secon-
dary prevention has changed to about 50%.
ICD (the middle panels): The total number of ICD
implants decreased from 386 to 281 within one year.
However, the percentage of ICD implanted for
secondary prevention was relatively high around 70
to 80%.
CRT-D (the bottom panel): The number of CRT-D
implantations for secondary prevention increased
from 114 to 195, and further, that for primary
prevention increased dramatically from 105 to 312,
around a three-fold increase. The percentage of
CRT-D implantations for primary prevention in-
creased from 47% in 2006 to 64% in the ﬁrst half of
the year in 2007, and then remained steady through-
out 2008.
Discussion
Base on several mega-trials4–7) on the primary
prevention of sudden cardiac death, the expansion of
indications for the use of ICD/CRT-D devices for
primary prevention and the number of implantations
of ICD/CRT-D devices has been increasing in the
USA and Europe.
In Japan, ICD was ﬁrst approved by the MHLW in
1996, which was 10 years behind the USA. The ﬁrst
CRT-D was also ﬁnally approved by the MHLW in
August of 2006. However, the current status of those
devices still remains unclear in Japan. Therefore, the
internet registry, JCDTR, which is administered by
the Japanese Heart Rhythm Society started in August
2006 in order to comprehend the actual conditions
and transition of the indications for the implantation
of ICD/CRT-D devices in Japanese patients.
Only new implantations of both ICD and CRT-D
devices and so-called upgrades from an ICD or
CRT-P to CRT-D performed from January 2006
were only enrolled in the JCDTR. The data from the
JCDTR has recently been reported.10,11) Further, the
number of facilities that enroll patients into the
JCDTR continues to gradually increase.
Comparing the current status of ICD implanta-
tions with other countries
Several worldwide surveys and registries have
examined ICD utilization.13–15) In the United States,
there were 82% primary and 18% secondary pre-
vention indications in the ICD therapy (ACT)
registry. On the other hand, there were 42% primary
and 58% secondary prevention indications in the
Italian ICD registry (IIR).16) In this study, the
percentage of patients receiving an implantation for
primary prevention gradually increased and then
stabilized at about 50%. Thus, the ratio of primary to
secondary prevention group in Japan was close to
that of the Italian ICD registry. However, there was a
big diﬀerence in comparison to that of the United
States, probably due to the diﬀerent guidelines and
clinical backgrounds in patients implanted with ICD
or CRT-D devices.
Clinical characteristics between primary and
secondary prevention
In comparing the patients implanted for primary
prevention with those for secondary prevention, a
lower LVEF, an NYHA class higher than class III,
Table 4 Complications in ICD/CRT-D implantations
ICD
(n ¼ 748)
CRT-D
(n ¼ 836)
Total
(n ¼ 1;584)
ICD vs
CRT-D
n (%) n (%) n (%)
Pneumothorax 6 (0.8) 6 (0.7) 12 (0.8) n.s
Cardiac tamponade 3 (0.4) 4 (0.5) 7 (0.4) n.s
Infection 2 (0.3) 3 (0.4) 5 (0.3) n.s
Exacerbation of CHF 1 (0.1) 1 (0.1) 2 (0.1) n.s
Cerebral infarction 0 (0.0) 1 (0.1) 1 (0.06) n.s
Death 0 (0.0) 1 (0.1) 1 (0.06) n.s
Bleeding/hematoma 5 (0.7) 8 (1.0) 13 (0.8) n.s
Dissection of the CS — 6 (0.7) 6 (0.4) —
LV dislodgment/failure — 3 (0.4) 3 (0.4) —
Twitching — 3 (0.4) 3 (0.4) —
Total 17 (2.3) 36 (4.3) 54 (3.4) p ¼ 0.023
CHF: congestive heart failure, CS: coronary sinus, LV: left ventricle
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Figure 2 Number of patients with ICD/CRT-D implantations and change in the purpose for the implantations.
The upper panel: number of implanted ICD/CRT-Ds (left panel) and the transition of the ICD/CRT-D implantations (right
panel) between the primary and secondary prevention groups. In the left panel, the number of patients in whom ICD/CRT-
Ds were implanted from January to May in 2008 was not shown.
The middle panel: number of implanted ICDs (left panel) and the transition of the ICD implantations (right panel) between
the primary and secondary prevention groups. In the left panel, the number of patients in whom ICDs were implanted from
January to May in 2008 was not shown.
The bottom panel: number of implanted CRT-Ds (left panel) and the transition of the CRT-Ds implantations (right panel)
between the primary and secondary prevention groups. In the left panel, the number of patients in whom CRT-Ds were
implanted from January to May in 2008 was not shown.
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and a greater amount of medications for heart failure
was observed in the primary prevention group.
Those data suggested that the ratio of severe heart
failure was relatively higher in the primary preven-
tion group than in the secondary prevention group.
Both IHD and DCM were the major structural
heart disease noted in the patients with an ICD/
CRT-D device, and were 84% in the primary
prevention group and 83% in the secondary pre-
vention group. The implantable deﬁbrillator devices
for primary prevention was signiﬁcantly lower in
IHD compared with CDM. Further, the ratio of
primary prevention to secondary prevention was 0.5
in patients with IHD and 1.1 in patients with DCM.
There may be several reasons why the implantation
for primary prevention in patient with IHD was
lower in Japan compared to that in the USA. One of
the major reasons is probably due to the diﬀerent
guideline for patients in IHD. Further, Japanese
physicians believe the risk in Japanese patients with
IHD and a lower LVEF is less than that in the USA.
Tanno et al.17) reported that it might be inappropriate
to apply MADIT II5) criteria to Japanese patients,
because the survival rate in their study was com-
parable with that in the MADIT II5) deﬁbrillator
group. They also stated the reason was that a
signiﬁcantly greater percentage of the more recent
patients were found to be in NYHA class I and that
they had undergone more percutaneous coronary
intervention procedures than in MADIT II.5)
Number and transition of indications for ICD and
CRT-D implantations
In this study, the percentage of ICD implanted for
secondary prevention remained steady throughout
2008. Inversely, the CRT-D implantations increased
and the ratio of CRT-D to ICD implantations
increased dramatically from 2006 to 2007. The
percentage of CRT-D implantations for primary
prevention had increased from 45% to 65% within a
half year. The speciﬁc reasons for the rapid increase
of the percentage of CRT-D prophylactic implanta-
tion are unclear. One of the major reasons is that
CRT-D was approved by Japanese MHLW in
August 2006. The others are the new guidelines
on ICD implantation, the favorable results of
COMPANION8) and MIRACLE18) trials, the pro-
gressive technologic advances of devices and the
cooperation between cardiologists in the heart failure
clinics and electrophysiologic laboratories of the
Japanese hospitals.
Conclusions:
This paper is the ﬁrst report from the JCDTR
database. We report the current status of implantable
deﬁbrillator devices in patients with a low LVEF of
540%, and observed the following ﬁndings; 1) the
percentage of patients receiving an implantation for
primary prevention gradually increased from 20% to
40% in 2006, and then stabilized at about 50%
through 2007, 2) in comparing the patients receiving
an implantation for primary prevention with those
implanted for secondary prevention, less IHD, more
DCM, a lower LVEF, a NYHA class higher than
class III, a greater amount of medications for CHF,
and more CRT-D implantations were observed, 3) an
expansion of the indications for ICD/CRT-D im-
plantations has been occurring recently, especially
CRT-D devices implanted for primary prevention.
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